Larotrectinib for treating NTRK fusion-positive solid tumours – guidance (TA630)

Larotrectinib is recommended for use within the Cancer Drugs Fund for NTRK fusion +ve solid tumours in adults and children only if the disease is locally advanced or metastatic or surgery could cause severe health problems and they have no satisfactory treatment options.

Source:

National Institute for Health and Care Excellence